Jinrang Kim,Haruka Okamoto,Andrew J. Murphy,Jesper Gromada,George D. Yancopoulos
申请号：
US16343240
公开号：
US20190248888A1
申请日:
2017.10.19
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present invention provides glucagon signaling pathway antagonists for use in combination with amino acid transport inhibitors, or mTOR inhibitors for lowering blood glucose levels in patients suffering from a disease or condition characterized in part by elevated blood glucose levels. According to certain embodiments of the invention, the glucagon signaling pathway antagonists are fully human antibodies that bind to human GCG or human GCGR. The antibodies of the invention, when combined with either SLC38A5 inhibitors or with an mTOR inhibitor are useful for lowering blood glucose levels, without resulting in alpha cell hyperplasia, and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.
